4.5 Review

Patterns of antiseizure medications prescribing in people with intellectual disability and epilepsy: A narrative review and analysis

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 89, Issue 7, Pages 2028-2038

Publisher

WILEY
DOI: 10.1111/bcp.15748

Keywords

antiseizure medications; intellectual disability; polypharmacy

Ask authors/readers for more resources

People with intellectual disabilities have a bidirectional relationship with epilepsy, with a significant proportion having seizures and intellectual impairment. Antiseizure medications (ASMs) are widely prescribed for people with intellectual disabilities in the UK, but there is limited understanding of current prescribing patterns and when and how to withdraw these medications. A narrative review and analysis of NHS Digital data were conducted to provide a comprehensive overview of ASM prescribing for people with intellectual disabilities. The study highlights the need to improve prescribing practices and further research in this complex area.
People with intellectual disabilities (PwID) have a bidirectional relationship with epilepsy. Nearly 25% of PwID have seizures and 30% people with epilepsy are thought to have a significant intellectual impairment. Furthermore, 70% of PwID are thought to have treatment-resistant epilepsy. In the United Kingdom, antiseizure medications (ASMs) are the second most widely prescribed psychotropic agent for PwID. However, it is unclear what the current evidence and patterns is on current prescribing of ASMs, including when and how a case is made to withdraw them. A narrative review along with an analysis of large-scale NHS Digital published data (2015-2020) on several aspects of ASM prescribing by general practices for PwID was undertaken. The review results and data analysis are consolidated and presented as 11 themes to provide a comprehensive overview of the study topic. Recent studies estimate that one-third and one-fifth of PwID are prescribed ASMs. A history of epilepsy is seen as the primary prescribing reason; however, often it is a legacy, and the indication is no longer clear. The proportion receiving ASMs continues to rise with age. This pattern of use does not correlate well with seizure onset. There are limited data on de-prescribing ASMs in PwID. The study population heterogenicity, associated polypharmacy, multimorbidity and higher sudden unexpected death in epilepsy risks are outlined. Suggestions are made from available evidence for improving prescribing practices for PwID and seizures, and key areas for further research in this complex clinical area are outlined.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available